Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific study shows benefits of Watchman for AF treatment

Boston Scientific study shows benefits of Watchman for AF treatment

13th May 2013

Boston Scientific has announced new data from a clinical study showing the benefits offered by its Watchman left atrial appendage closure device in the treatment of atrial fibrillation (AF).

Four-year follow-up data from the Protect AF trial showed that Watchman was statistically superior to warfarin for preventing cardiovascular death, all-cause stroke and systemic embolisation among AF patients.

Significant reductions in both cardiovascular and all-cause fatalities were associated with the device, which was approved for sale in Europe in 2005, though it remains limited to investigational use in the US.

This underlines Watchman's potential to prevent stroke incidents and save lives more effectively than the current standard of care for AF.

Dr Vivek Reddy of the Mount Sinai School of Medicine in New York, principal investigator of the Protect AF trial, said: "This is a significant development because for the first time we were able to demonstrate that the Watchman device was superior to warfarin for both primary efficacy and also mortality."

Earlier this month, Boston Scientific announced the completion of a first-in-human clinical trial utilising the IntellaTip MiFi XP Ablation Catheter for the treatment of atrial flutter.ADNFCR-8000103-ID-801584701-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.